TY - JOUR
T1 - Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia
T2 - The EBMT transplant consensus
AU - Dreger, P.
AU - Corradini, P.
AU - Kimby, E.
AU - Michallet, M.
AU - Milligan, D.
AU - Schetelig, J.
AU - Wiktor-Jedrzejczak, W.
AU - Niederwieser, D.
AU - Hallek, M.
AU - Montserrat, E.
PY - 2007/1
Y1 - 2007/1
N2 - The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option for patients with B-cell chronic lymphocytic leukemia (CLL). Based on a MEDLINE search and additional sources, a consented proposal was drafted, refined and approved upon final discussion by an international expert panel. Key elements of the consensus are (1) allo-SCT is a procedure with evidence-based efficacy in poor-risk CLL; (2) although definition of 'poor-risk CLL' requires further investigation, allo-SCT is a reasonable treatment option for younger patients with (i) non-response or early relapse (within 12 months) after purine analogues, (ii) relapse within 24 months after having achieved a response with purine-analogue-based combination therapy or autologous transplantation, and (iii) patients with p53 abnormalities requiring treatment; and (3) optimum transplant strategies may vary according to distinct clinical situations and should be defined in prospective trials. This is the first attempt to define standard indications for allo-SCT in CLL. Nevertheless, whenever possible, allo-SCT should be performed within disease-specific prospective clinical protocols in order to continuously refine transplant indications according to new developments in risk assessment and treatment of CLL.
AB - The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option for patients with B-cell chronic lymphocytic leukemia (CLL). Based on a MEDLINE search and additional sources, a consented proposal was drafted, refined and approved upon final discussion by an international expert panel. Key elements of the consensus are (1) allo-SCT is a procedure with evidence-based efficacy in poor-risk CLL; (2) although definition of 'poor-risk CLL' requires further investigation, allo-SCT is a reasonable treatment option for younger patients with (i) non-response or early relapse (within 12 months) after purine analogues, (ii) relapse within 24 months after having achieved a response with purine-analogue-based combination therapy or autologous transplantation, and (iii) patients with p53 abnormalities requiring treatment; and (3) optimum transplant strategies may vary according to distinct clinical situations and should be defined in prospective trials. This is the first attempt to define standard indications for allo-SCT in CLL. Nevertheless, whenever possible, allo-SCT should be performed within disease-specific prospective clinical protocols in order to continuously refine transplant indications according to new developments in risk assessment and treatment of CLL.
UR - http://www.scopus.com/inward/record.url?scp=33845543049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845543049&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404441
DO - 10.1038/sj.leu.2404441
M3 - Article
C2 - 17109028
AN - SCOPUS:33845543049
VL - 21
SP - 12
EP - 17
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 1
ER -